Utah’s recent announcement that it was partnering with a health tech startup that will use artificial intelligence to renew drug prescriptions may offer a glimpse of the futuristic version of AI medicine that’s long been foretold by technologists and venture capitalists.
But it’s only possible because of some pre-approved rule breaking — and may prove a broader test of the Food and Drug Administration’s authority to evaluate a new wave of clinical AI products, according to interviews with executives and experts.
In January, Utah regulators said they had signed an agreement with a startup called Doctronic to launch an AI system that will perform a clinical evaluation of patients and, when deemed appropriate, renew some 200 common medications autonomously.
This article is exclusive to STAT+ subscribers
Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.
Already have an account? Log in
